Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

5.150 +0.390 (+8.19%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2026 Add to My Watchlist

Price and Volume

Volume	185,146
Open	4.770
Bid (Size)	5.150 (2,000)
Ask (Size)	5.490 (100)
Prev. Close	4.760
Today's Range	4.720 - 5.260
52wk Range	3.920 - 19.14
Shares Outstanding	101,102,152
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit

May 05, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

May 05, 2026

From Pomerantz LLP

Via GlobeNewswire

Performance

YTD	-71.0%	-71.0%
1 Month	+5.7%	+5.7%
3 Month	+2.2%	+2.2%
6 Month	-58.1%	-58.1%
1 Year	-29.0%	-29.0%

More News

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 05, 2026

From Schall Law

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

May 02, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 01, 2026

From Schall Law

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit

April 28, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

April 28, 2026

From Pomerantz LLP

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 28, 2026

From Schall Law

Via GlobeNewswire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

April 25, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 24, 2026

From Schall Law

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

April 21, 2026

From Pomerantz LLP

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 21, 2026

From Schall Law

Via GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

April 18, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit

April 17, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 17, 2026

From Schall Law

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

April 14, 2026

From Pomerantz LLP

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 14, 2026

From Schall Law

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit

April 10, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 10, 2026

From Schall Law

Via GlobeNewswire

ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role

April 07, 2026

From Kirby McInerney LLP

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

April 07, 2026

From Pomerantz LLP

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 07, 2026

From Schall Law

Via GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

April 06, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ATRA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Atara Biotherapeutics, Inc. Investors - Contact Kirby McInerney LLP by May 22, 2026

April 03, 2026

From Kirby McInerney LLP

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 03, 2026

From Schall Law

Via GlobeNewswire

Frequently Asked Questions

Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?

Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.

What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?

Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?

The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market

What is the current price of Atara Biotherapeutics, Inc. - Common Stock?

The current price of Atara Biotherapeutics, Inc. - Common Stock is 5.150

When was Atara Biotherapeutics, Inc. - Common Stock last traded?

The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 05/06/26 04:00 PM ET

What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?

The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 520.68M

How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?

Atara Biotherapeutics, Inc. - Common Stock has 521M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.